Amgen Announces Voting Results of Annual Meeting of Stockholders
Amgen (NASDAQ:AMGN), today announced results of voting at the company’s
Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake
Village in Westlake Village, Calif. Approximately 86.9 percent of
outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Jerry D.
Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer,
Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer
and Kevin W. Sharer were each reelected to Amgen’s
Board of Directors, each receiving a majority of ‘For’
votes of the votes cast and each was elected by no less than 87.7
percent of the votes cast. With the reelection of these directors, Amgen
currently has 11 directors.
With approximately 97.6 percent of ‘For’
votes of the votes cast, stockholders ratified Ernst & Young as Amgen’s
independent registered public accountants for the year ending Dec. 31,
2008.
Stockholders approved a nonbinding resolution recommending that the
company eliminate the supermajority voting requirements in its bylaws
and certificate of incorporation. The proposal received approximately
78.7 percent of votes cast ‘For’
the proposal. Stockholders rejected a proposal relating to animal
welfare. The proposal received less than 4.9 percent of the votes cast ‘For’
the proposal.
The final vote totals will be included in the company's next quarterly
report to be filed with the Securities and Exchange Commission.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science’s
promise by bringing safe and effective medicines from lab, to
manufacturing plant, to patient. Amgen therapeutics have changed the
practice of medicine, helping millions of people around the world in the
fight against cancer, kidney disease, rheumatoid arthritis and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people’s lives. To learn more about
our pioneering science and our vital medicines, visit www.amgen.com.
